| 1. Han KP, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, Vyas VV, Marcus WD, Chavaillaz PA, Romero CA et al.. (2011) IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization.. Cytokine, 56 (3): (804-10). [PMID:22019703] |
| 2. Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, Liu B, Zhu X, Wen J, You L et al.. (2016) Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.. Cancer Immunol Res, 4 (1): (49-60). [PMID:26511282] |
| 3. Robinson TO, Schluns KS. (2017) The potential and promise of IL-15 in immuno-oncogenic therapies.. Immunol Lett, 190 (3): (159-168). [PMID:28823521] |
| 4. Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE et al.. (2018) First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.. Blood, 131 (23): (2515-2527). [PMID:29463563] |
| 5. Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K et al.. (2018) ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.. Lancet Oncol, 19 (5): (694-704). [PMID:29628312] |
| 6. Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC et al.. (2018) Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.. Clin Cancer Res, 24 (22): (5552-5561). [PMID:30045932] |
| 7. Van der Meer JMR, Maas RJA, Guldevall K, Klarenaar K, de Jonge PKJD, Evert JSH, van der Waart AB, Cany J, Safrit JT, Lee JH et al.. (2021) IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells.. Cancer Immunol Immunother, 70 (5): (1305-1321). [PMID:33140189] |
| 8. Huang J, Shiao SL, Furuya H, Rosser CJ. (2019) Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature.. J Immunother, 42 (9): (354-358). [PMID:31107371] |
